课题基金 / 基金详情

Population Pharmacokinetic Modeling and Optimal Control

Population Pharmacokinetic Modeling and Optimal Control
群体药代动力学建模和最优控制
批准号:
6756435
负责人:
Roger W. Jelliffe
金额:
$22.37万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-06-15 至 2007-05-31

项目摘要

项目成果

Roger W. Jelliffe的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This proposal is to develop new tools to optimize population drug modeling and individualized therapy. Aim 1 will develop new methods for consistent and efficient parametric population modeling using low -discrepancy Faure integration methods. Aim 2 will develop new methods for determining confidence intervals for nonparametric population analysis using profile likelihood techniques. Aim 3 develops a new approach to stochastic dosage optimization using the latest sampling-based methods in nonlinear filtering and a novel method for solving the Bellman stochastic dynamic programming equations. This work will have a broad impact on population modeling and patient care. Most researchers and clinicians now use parametric (P) methods which are not statistically consistent. Much effort is spent on clinical ananlyses using those flawed methods. The new consistent and efficient P method in Aim 1 will be a major advance that will put maximum likelihood P population modeling on a sound statistical footing. Nonparametric (NP) methods of population analysis are also consistent. They can in addition handle mixture distributions from genetically polymorphic populations, and are suitable for "multiple model" (MM) optimal dosage design. However, computationally intensive bootstrap methods are the only current way to obtain NP confidence intervals. Aim 2 will provide a new, more efficient, route to these intervals. Then both P and NP consistent methods will be available to the health care community. NP population modeling is a tool for optimal MM design of coordinated combination dosage regimens of toxic drugs for treatment of AIDS, cancer, infectious diseases, and transplant patients. This, plus feedback from serum, effect, and toxicity measurements can now be combined into a new and unique paradigm for planning and optimizing the entire process of learning about drug behavior in patients while treating them at the same time. This is Aim 3. Such a tool does not exist at present, to our kowledge. For any planned duration of therapy, one will be able to coordinate both the amounts and timing of the doses, and the number and timing of the measurements. The result will be an active therapeutic strategy which achieves desired target goals with optimal precision, rehearsing many future scenarios in advance (this is new). In all three Aims, the end product will be widely disseminated software with user interfaces for research and clinical use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimizing Coordinated Combination Drug Therapy
  • 批准号:
    7248652
  • 项目类别:
  • 资助金额:
    $53.9万
  • 财政年份:
    2006
  • 负责人:
    Roger W. Jelliffe
  • 依托单位:
Optimizing Coordinated Combination Drug Therapy
  • 批准号:
    7667429
  • 项目类别:
  • 资助金额:
    $58.0万
  • 财政年份:
    2006
  • 负责人:
    Roger W. Jelliffe
  • 依托单位:
Optimizing Coordinated Combination Drug Therapy
  • 批准号:
    7423963
  • 项目类别:
  • 资助金额:
    $53.99万
  • 财政年份:
    2006
  • 负责人:
    Roger W. Jelliffe
  • 依托单位:
Optimizing Coordinated Combination Drug Therapy
  • 批准号:
    7139743
  • 项目类别:
  • 资助金额:
    $50.98万
  • 财政年份:
    2006
  • 负责人:
    Roger W. Jelliffe
  • 依托单位:
国内基金
海外基金
O6-methyl-dGTP抑制胶质母细胞瘤的作用及分子机制研究
  • 批准号:
    82304565
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    李瑾
  • 依托单位:
基于Notch-1介导miR-200家族调控上皮间质转化对绒癌耐药机制的研究
  • 批准号:
    81972428
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2019
  • 负责人:
    安瑞芳
  • 依托单位:
地塞米松诱导的人卵巢癌对化疗药物耐受及其机制的研究
维生素B3促进化疗导致粒细胞减少症的中性粒细胞生成功能及作用机制研究
  • 批准号:
    81060045
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2010
  • 负责人:
    蓝丹
  • 依托单位: